Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …

Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

DNA mismatch repair deficiency (MMRd) is associated with a high tumor mutational burden
(TMB) and sensitivity to immune checkpoint blockade (ICB) therapy. Nevertheless, most …

Background High tumor mutation burden (TMB-H) has been proposed as a predictive
biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for …

Within the past decade, the field of immunotherapy has revolutionized the treatment of many
cancers with the development and regulatory approval of various immune-checkpoint …

Most (if not all) tumors emerge and progress under a strong evolutionary pressure imposed
by trophic, metabolic, immunological, and therapeutic factors. The relative impact of these …

Neoadjuvant immune checkpoint blockade has shown promising clinical activity. Here, we
characterized early kinetics in tumor-infiltrating and circulating immune cells in oral cancer …

Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …

Checkpoint inhibitors (CPIs) augment adaptive immunity. Systematic pan-tumor analyses
may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features …

Only a fraction of patients with cancer respond to immune checkpoint blockade (ICB)
treatment, but current decision-making procedures have limited accuracy. In this study, we …